Lipid metabolism as a target for cancer drug resistance: progress and prospects

被引:29
作者
Wang, Zi'an [1 ,2 ]
Wang, Yueqin [1 ,2 ]
Li, Zeyun [1 ,2 ]
Xue, Wenhua [1 ,2 ]
Hu, Shousen [3 ]
Kong, Xiangzhen [1 ,2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Pharm, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Henan Key Lab Precis Clin Pharm, Zhengzhou, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Zhengzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
drug resistance; lipid metabolism; combination drug; inhibitor; chemotherapy resistance; targeted therapy; FATTY-ACID SYNTHASE; STEAROYL-COA DESATURASE; ERBB-2 ONCOGENE OVEREXPRESSION; BREAST-CANCER; THERAPEUTIC TARGET; IN-VIVO; CHOLESTEROL; CELLS; CHEMOTHERAPY; EXPRESSION;
D O I
10.3389/fphar.2023.1274335
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is the world's leading cause of human death today, and the treatment process of cancer is highly complex. Chemotherapy and targeted therapy are commonly used in cancer treatment, and the emergence of drug resistance is a significant problem in cancer treatment. Therefore, the mechanism of drug resistance during cancer treatment has become a hot issue in current research. A series of studies have found that lipid metabolism is closely related to cancer drug resistance. This paper details the changes of lipid metabolism in drug resistance and how lipid metabolism affects drug resistance. More importantly, most studies have reported that combination therapy may lead to changes in lipid-related metabolic pathways, which may reverse the development of cancer drug resistance and enhance or rescue the sensitivity to therapeutic drugs. This paper summarizes the progress of drug design targeting lipid metabolism in improving drug resistance, and providing new ideas and strategies for future tumor treatment. Therefore, this paper reviews the issues of combining medications with lipid metabolism and drug resistance.
引用
收藏
页数:12
相关论文
共 94 条
[1]   Steroidal Triterpenes of Cholesterol Synthesis [J].
Acimovic, Jure ;
Rozman, Damjana .
MOLECULES, 2013, 18 (04) :4002-4017
[2]   Emerging roles of fatty acid metabolism in cancer and their targeted drug development [J].
An, Qi ;
Lin, Rui ;
Wang, Dongmei ;
Wang, Chuan .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240
[3]   Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis [J].
Ashrafian, H .
LANCET, 2006, 367 (9510) :618-621
[4]   Fatty acid synthase: A metabolic oncogene in prostate cancer? [J].
Baron, A ;
Migita, T ;
Tang, D ;
Loda, M .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (01) :47-53
[5]   Cancer Focus Lipid metabolism and cancer [J].
Bian, Xueli ;
Liu, Rui ;
Meng, Ying ;
Xing, Dongming ;
Xu, Daqian ;
Lu, Zhimin .
JOURNAL OF EXPERIMENTAL MEDICINE, 2021, 218 (01)
[6]   Metabolic pathways promoting cancer cell survival and growth [J].
Boroughs, Lindsey K. ;
DeBerardinis, Ralph J. .
NATURE CELL BIOLOGY, 2015, 17 (04) :351-359
[7]   Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention [J].
Butler, Lisa M. ;
Perone, Ylenia ;
Dehairs, Jonas ;
Lupien, Leslie E. ;
de Laat, Vincent ;
Talebi, Ali ;
Loda, Massimo ;
Kinlaw, William B. ;
Swinnen, Johannes V. .
ADVANCED DRUG DELIVERY REVIEWS, 2020, 159 :245-293
[8]  
Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066
[9]   High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer [J].
Chen, Qiufang ;
Pan, Zhenzhen ;
Zhao, Min ;
Wang, Qin ;
Qiao, Chen ;
Miao, Liyun ;
Ding, Xuansheng .
JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (09) :6722-6732
[10]   Research progress of sophoridine's pharmacological activities and its molecular mechanism: an updated review [J].
Chen, Yiwei ;
Wang, Xiang ;
Ye, Dongmei ;
Yang, Zhousheng ;
Shen, Qingrong ;
Liu, Xiaoxia ;
Chen, Chunxia ;
Chen, Xiaoyu .
FRONTIERS IN PHARMACOLOGY, 2023, 14